Injectable on-demand treatments for children with hereditary angioedema (HAE) are often associated with anxiety, pain, treatment delays, and high use of emergency healthcare services, highlighting the need for a simpler treatment option, according to data from Kalvista Pharmaceuticals, the company that markets Ekterly (sebetralstat), an oral on-demand…